AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8610901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1427925 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia and reperfusion (Group I, 80 patients)
Number of subjects: 266
Study 1427925 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade and retrograde cardioplegia with antegrade reperfusion (Group II, 98 patients)
Number of subjects: 266
Study 1427925 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade and retrograde cardioplegia with retrograde reperfusion (Group III, 88 patients)
Number of subjects: 266
Study 3883822 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole gut irrigation alone
Number of subjects: 148
Study 3883822 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole gut irrigation + metronidazole
Number of subjects: 148
Study 3883822 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole gut irrigation + metronidazole + ampicillin
Number of subjects: 148
Study 3883822 — intervention group
Group type: COMPARATOR
Intervention: Control (no whole gut irrigation)
Number of subjects: 148
Study 3883822 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole gut irrigation (clean bowel)
Number of subjects: 148
Study 31386636 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin (HbA1c)
Number of subjects: 376644
Study 31386636 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin (HbA1c) after excluding potentially invalid SNPs
Number of subjects: 376644
Study 30365263 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus moxibustion
Number of subjects: 58
Study 30365263 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 58
Study 26634642 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT-18 (180 mg, once weekly for 4 weeks)
Number of subjects: 12
Study 26634642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26179672 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (80 mg)
Number of subjects: 212
Study 26179672 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 212
Study 23868016 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression treatment completion
Number of subjects: 30
Study 23868016 — intervention group
Group type: COMPARATOR
Intervention: Barriers to treatment
Number of subjects: 30
Study 21172497 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time three-dimensional echocardiography (RT3DE)
Number of subjects: 52
Study 21172497 — intervention group
Group type: COMPARATOR
Intervention: Two-dimensional echocardiography
Number of subjects: 52
Study 19088351 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline ICUs
Number of subjects: 1118
Study 19088351 — intervention group
Group type: COMPARATOR
Intervention: Control ICUs
Number of subjects: 1118
Study 16564209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy (HT)
Number of subjects: 50
Study 16564209 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (CP)
Number of subjects: 50
Study 16564209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy (HT) and Conventional physiotherapy (CP)
Number of subjects: 50
Study 15192622 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy for 30 months
Number of subjects: 17
Study 15192622 — intervention group
Group type: COMPARATOR
Intervention: Coenzyme Q(10) for 1 year
Number of subjects: 17
Study 11084173 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg vaginal misoprostol
Number of subjects: 152
Study 11084173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 9136529 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelseal graft
Number of subjects: 44
Study 9136529 — intervention group
Group type: COMPARATOR
Intervention: Hemashield graft
Number of subjects: 44
Study 8151187 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG 0.05 mg + 6 x 10(8) KML
Number of subjects: 860
Study 8151187 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (i.v.)
Number of subjects: 860
Study 8151187 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG 0.05 mg + 5 x 10(7) KML
Number of subjects: 860
Study 8151187 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG 0.01 mg + 5 x 10(7) KML
Number of subjects: 860
Study 3731087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine 2 g/m2/72 h by continuous infusion
Number of subjects: 0
Study 3731087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine 6 g/m2/72 h by continuous infusion
Number of subjects: 0
Study 29808043 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet for 12 weeks
Number of subjects: 74
Study 26885785 — intervention group
Group type: EXPERIMENTAL
Intervention: clin 1.0%-BP 3.75% gel
Number of subjects: 0
Study 26885785 — intervention group
Group type: COMPARATOR
Intervention: adap 0.1%-BP 2.5% gel
Number of subjects: 0
Study 24530883 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation with resistance training (CR+RT)
Number of subjects: 60
Study 24530883 — intervention group
Group type: COMPARATOR
Intervention: Creatine (CR)
Number of subjects: 60
Study 24530883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 60
Study 22960587 — intervention group
Group type: EXPERIMENTAL
Intervention: TEENCOPE (Internet coping skills training)
Number of subjects: 320
Study 22960587 — intervention group
Group type: COMPARATOR
Intervention: Managing Diabetes (Internet educational intervention)
Number of subjects: 320
Study 20473995 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasonography screening
Number of subjects: 12639
Study 20473995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 12639
Study 18838564 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3261
Study 18838564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3261
Study 18838564 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 3261
Study 15947765 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of cyclic variation (CV) of myocardial integrated backscatter (IBS)
Number of subjects: 80
Study 15947765 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized time delay (NTD)
Number of subjects: 80
Study 15947765 — intervention group
Group type: EXPERIMENTAL
Intervention: NTD greater than 1.35 as the optimal cutoff
Number of subjects: 80
Study 11683668 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance 1
Number of subjects: 10
Study 11683668 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance 2
Number of subjects: 10
Study 9401251 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg daily, 20 mg during diarrhea)
Number of subjects: 86
Study 9401251 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 8429445 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bovine lung surfactant extract (beractant), 4 doses administered.
Number of subjects: 56
Study 8429445 — intervention group
Group type: COMPARATOR
Intervention: Control group (equal volume of air administered).
Number of subjects: 56
Study 2887614 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine at night
Number of subjects: 336
Study 2887614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 29614274 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 51
Study 29614274 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 51
Study 29614274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (0.25% bupivacaine and normal saline)
Number of subjects: 51
Study 26834240 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles of ABVD (2×ABVD; n = 137)
Number of subjects: 287
Study 26834240 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles of AVD (2×AVD; n = 82)
Number of subjects: 287
Study 26834240 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of ABVD (4×ABVD; n = 68)
Number of subjects: 287
Study 26834240 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles of ABVD/AVD
Number of subjects: 287
Study 23426565 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme (n = 13)
Number of subjects: 25
Study 23426565 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group, n = 12)
Number of subjects: 25
Study 20720400 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention in primary care setting
Number of subjects: 4009
Study 20037567 — intervention group
Group type: EXPERIMENTAL
Intervention: milgamma in combination with diclofenac
Number of subjects: 38
Study 20037567 — intervention group
Group type: COMPARATOR
Intervention: diclofenac only
Number of subjects: 38
Study 16810105 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoFab (250 units/kg loading dose, followed by 50 units/kg every 12 hrs for 9 doses)
Number of subjects: 81
Study 16810105 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoFab
Number of subjects: 81
Study 16810105 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 mg/kg human albumin)
Number of subjects: 81
Study 16810105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 12830736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 0
Study 11061539 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment with 6 IU/m2 body surface/day
Number of subjects: 79
Study 11061539 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment with 3 IU/m2 body surface/day
Number of subjects: 79
Study 11061539 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (both dosages)
Number of subjects: 79
Study 11061539 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment in GHD children
Number of subjects: 79
Study 11061539 — intervention group
Group type: COMPARATOR
Intervention: Untreated children with short stature born SGA
Number of subjects: 79
Study 9246281 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 40
Study 8299405 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g EDTA per infusion over a period of 5‐9 weeks to a total of 57 g EDTA
Number of subjects: 29
Study 8299405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 29
Study 2852945 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol palmitate (300,000 I.U. daily)
Number of subjects: 181
Study 2852945 — intervention group
Group type: COMPARATOR
Intervention: Control (no retinol palmitate)
Number of subjects: 181
Study 29405231 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month care management intervention
Number of subjects: 32
Study 29405231 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 32
Study 28800753 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal prevention program (6 school hours)
Number of subjects: 2342
Study 28800753 — intervention group
Group type: COMPARATOR
Intervention: No treatment control condition
Number of subjects: 2342
Study 25681001 — intervention group
Group type: EXPERIMENTAL
Intervention: sub-Bowman keratomileusis (100-μm flap)
Number of subjects: 100
Study 25681001 — intervention group
Group type: COMPARATOR
Intervention: laser in situ keratomileusis (LASIK) (120-μm flap)
Number of subjects: 100
Study 23800004 — intervention group
Group type: COMPARATOR
Intervention: Nellcor pulse oximeter (PO)
Number of subjects: 44
Study 23800004 — intervention group
Group type: COMPARATOR
Intervention: Masimo pulse oximeter (PO)
Number of subjects: 44
Study 20056851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 3
Study 20056851 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 3
Study 20056851 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 3
Study 18203048 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 600 mg/day
Number of subjects: 16
Study 18203048 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 400 mg/day
Number of subjects: 16
Study 18203048 — intervention group
Group type: COMPARATOR
Intervention: Clozapine and placebo
Number of subjects: 16
Study 20717044 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib (20 mg intravenous)
Number of subjects: 380
Study 20717044 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN patch 10 mg/h)
Number of subjects: 380
Study 20717044 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 380
Study 20717044 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 380
Study 20717044 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN
Number of subjects: 380
Study 16009103 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpi Qinghua Recipe (JPQHR) combined with routine therapy
Number of subjects: 106
Study 16009103 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 106
Study 12632840 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin per day
Number of subjects: 5804
Study 12632840 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5804
Study 9785773 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of preventive measures for soccer and running injuries
Number of subjects: 0
Study 9785773 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ankle stabilisers and/or proprioceptive ankle disc training
Number of subjects: 0
Study 9785773 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee brace
Number of subjects: 0
Study 9785773 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Number of subjects: 0
Study 9785773 — intervention group
Group type: COMPARATOR
Intervention: Stretching, taping, mental training, controlled rehabilitation
Number of subjects: 0
Study 7974685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin, 150‐200 micrograms/kg in a single dose
Number of subjects: 60
Study 7974685 — intervention group
Group type: COMPARATOR
Intervention: Albendazole, 400 mg/d for 3 days
Number of subjects: 60
Study 7974685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin, 150‐200 micrograms/kg in a single dose (second treatment course)
Number of subjects: 60
Study 3141982 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 weekly fractions of 2 Gy without any prior laparotomy
Number of subjects: 516
Study 3141982 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weekly fractions of 3.3 Gy after laparotomy
Number of subjects: 516
Study 3141982 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 2.5 Gy
Number of subjects: 516
Study 3141982 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 x 2 Gy
Number of subjects: 516
Study 3141982 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 3.3 Gy
Number of subjects: 516
Study 3141982 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with previous laparotomy
Number of subjects: 516
Study 3141982 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without previous abdominal surgery
Number of subjects: 516
Study 30061240 — intervention group
Group type: EXPERIMENTAL
Intervention: dMMR/met+
Number of subjects: 134
Study 30061240 — intervention group
Group type: COMPARATOR
Intervention: pMMR/met+
Number of subjects: 134
Study 30061240 — intervention group
Group type: COMPARATOR
Intervention: dMMR/met-
Number of subjects: 134
Study 30061240 — intervention group
Group type: COMPARATOR
Intervention: pMMR/met-
Number of subjects: 134
Study 26154086 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (12 mg/kg)
Number of subjects: 48
Study 26154086 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans‐chalcone (12 mg/kg)
Number of subjects: 48
Study 26154086 — intervention group
Group type: COMPARATOR
Intervention: Grape seed oil (control for trans‐chalcone)
Number of subjects: 48
Study 23034474 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU/d)
Number of subjects: 23
Study 23034474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21121175 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg)
Number of subjects: 22
Study 21121175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18430910 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-based treatment (n = 341): fluorouracil (1000 mg/m2 on days 1-4 and 29-32) + mitomycin (10 mg/m2 on days 1 and 29) + radiotherapy (45-59 Gy)
Number of subjects: 682
Study 18430910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based treatment (n = 341): fluorouracil (1000 mg/m2 on days 1-4, 29-32, 57-60, and 85-88) + cisplatin (75 mg/m2 on days 1, 29, 57, and 85) + radiotherapy (45-59 Gy; start day = day 57)
Number of subjects: 682
Study 17003663 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (FLV)
Number of subjects: 128
Study 17003663 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo (PBO)
Number of subjects: 128
Study 14581268 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery and radiotherapy
Number of subjects: 179
Study 14581268 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 179
Study 14581268 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery
Number of subjects: 179
Study 10812869 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8865702 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia (GOI)
Number of subjects: 28
Study 8865702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (GOI + fentanyl 4.8 +/- 0.9 micrograms . kg‐1)
Number of subjects: 28
Study 8865702 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural (GOI + continuous epidural infusion 1.5% lidocaine, 5 ml . h‐1)
Number of subjects: 28
Study 1371291 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (1, 5, 10, 50, or 100 mg/day for 7 days)
Number of subjects: 69
Study 1371291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 1371291 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (various doses)
Number of subjects: 69
Study 1371291 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (2 days treatment)
Number of subjects: 69
Study 6653057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally at bedtime for four days
Number of subjects: 10
Study 6653057 — intervention group
Group type: COMPARATOR
Intervention: Oxtriphylline 200 mg (equivalent to theophylline 135 mg) orally every eight hours for 10 doses
Number of subjects: 10
Study 29611316 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical clowns (MCs)
Number of subjects: 140
Study 29611316 — intervention group
Group type: COMPARATOR
Intervention: Control (technician)
Number of subjects: 140
Study 27339398 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time BM-MSC transplantation (5 × 10^7 BM-MSCs)
Number of subjects: 72
Study 27339398 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-time BM-MSC transplantation (5 × 10^7 BM-MSCs)
Number of subjects: 72
Study 27339398 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time BM-MSC transplantation
Number of subjects: 72
Study 27339398 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-time BM-MSC transplantation
Number of subjects: 72
Study 27339398 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 24624390 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement followed by monthly supportive periodontal therapy
Number of subjects: 28
Study 24624390 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth ultrasonic debridement followed by supportive periodontal therapy at 3-month intervals
Number of subjects: 28
Study 22156722 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex PTSD patients
Number of subjects: 49
Study 22156722 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 49
Study 19962354 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 10 mg/day
Number of subjects: 62
Study 19962354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 19962354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75, 150, 300, and 600 mg/day)
Number of subjects: 62
Study 18953194 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop intervention consisting of discussions, didactic information, individual plan formulation, and strategies to cope with moral distress.
Number of subjects: 0
Study 16914210 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen plus honey
Number of subjects: 60
Study 16914210 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 60
Study 15165934 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 100 mg/day
Number of subjects: 122
Study 15165934 — intervention group
Group type: EXPERIMENTAL
Intervention: irbesartan 300 mg/day
Number of subjects: 122
Study 15165934 — intervention group
Group type: EXPERIMENTAL
Intervention: candesartan 16 mg/day
Number of subjects: 122
Study 15165934 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 122
Study 11470339 — intervention group
Group type: EXPERIMENTAL
Intervention: Committed Quitters Program (CQP)
Number of subjects: 3683
Study 11470339 — intervention group
Group type: COMPARATOR
Intervention: User's Guide (UG)
Number of subjects: 3683
Study 9415793 — intervention group
Group type: EXPERIMENTAL
Intervention: PeaceBuilders program (intervention schools)
Number of subjects: 7
Study 9415793 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 7
Study 8518337 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 40
Study 8518337 — intervention group
Group type: COMPARATOR
Intervention: Amiloride-hydrochlorothiazide
Number of subjects: 40
Study 2433081 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg orally 2 h before and 10 mg at the start of the infusion)
Number of subjects: 7
Study 2433081 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg 3 h before the infusion)
Number of subjects: 7
Study 2433081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7